Australia markets closed

Xenon Pharmaceuticals Inc. (XENE)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
37.65-0.50 (-1.31%)
At close: 04:00PM EST
36.20 -1.45 (-3.85%)
After hours: 06:28PM EST
Currency in USD

Valuation measures4

Market cap (intra-day) 2.39B
Enterprise value 1.76B
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)166.43
Price/book (mrq)3.17
Enterprise value/revenue 133.25
Enterprise value/EBITDA -16.08

Trading information

Stock price history

Beta (5Y monthly) 1.36
52-week change 338.83%
S&P500 52-week change 3-9.85%
52-week high 341.39
52-week low 324.94
50-day moving average 336.98
200-day moving average 334.49

Share statistics

Avg vol (3-month) 3387.79k
Avg vol (10-day) 3288.22k
Shares outstanding 562.54M
Implied shares outstanding 6N/A
Float 857.42M
% held by insiders 11.70%
% held by institutions 195.77%
Shares short (12 Jan 2023) 43.63M
Short ratio (12 Jan 2023) 48.75
Short % of float (12 Jan 2023) 45.87%
Short % of shares outstanding (12 Jan 2023) 45.80%
Shares short (prior month 14 Dec 2022) 43.82M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)29 Sept 2022

Profitability

Profit margin 0.00%
Operating margin (ttm)-840.10%

Management effectiveness

Return on assets (ttm)-13.30%
Return on equity (ttm)-22.66%

Income statement

Revenue (ttm)13.17M
Revenue per share (ttm)0.21
Quarterly revenue growth (yoy)-98.40%
Gross profit (ttm)-57.03M
EBITDA -109.27M
Net income avi to common (ttm)-113.54M
Diluted EPS (ttm)-1.56
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)638.19M
Total cash per share (mrq)10.2
Total debt (mrq)7.16M
Total debt/equity (mrq)0.95
Current ratio (mrq)41.78
Book value per share (mrq)12.04

Cash flow statement

Operating cash flow (ttm)-86.41M
Levered free cash flow (ttm)-53.1M